Et stort randomiseret fase III- studie, med 429 tidligere ubehandlede patienter med metastatisk sygdom, er blevet udført med doxorubicin (50 mg/ m2) i kombination med docetaxel (75 mg/ 2) (AT arm) versus doxorubicin (60 mg/ m2) i kombination med cyclophosfamid (600 mg/ m2) (AC arm).
One large randomized phase III study, involving 429 previously untreated patients with metastatic disease, has been performed with doxorubicin (50 mg/ m²) in combination with docetaxel (75 mg/ m²) (AT arm) versus doxorubicin (60 mg/ m²) in combination with cyclophosphamide (600 mg/ m²) (AC arm).